{"id":748444,"date":"2023-04-18T07:05:52","date_gmt":"2023-04-18T11:05:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\/"},"modified":"2023-04-18T07:05:52","modified_gmt":"2023-04-18T11:05:52","slug":"jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\/","title":{"rendered":"Jeune Aesthetics Announces Dosing of First Subject in Phase 1, Cohort 3 Study of KB301 for the Improvement of Lateral Canthal Lines at Rest"},"content":{"rendered":"
\n

PITTSBURGH, April 18, 2023 (GLOBE NEWSWIRE) — Jeune Aesthetics, Inc.<\/u><\/a> (\u201cJeune\u201d), a wholly-owned subsidiary of Krystal Biotech, Inc.<\/u><\/a> (\u201cKrystal\u201d) (NASDAQ: KRYS), today announced treatment of the first subject in the Phase 1, Cohort 3 study of KB301 for the improvement of lateral canthal lines at rest. Jeune\u2019s lead product candidate, KB301, delivers the human COL3A1<\/em> gene to targeted skin cells that in turn produce natural type 3 collagen. Natural collagen 3 is the first in a pipeline of key skin proteins that Jeune plans to advance through clinical development to create a new category of regenerative aesthetic medicines designed to address \u2013 and potentially reverse \u2013 biological changes in aging skin.<\/p>\n

The Phase 1, Cohort 3 study is being conducted at a single center as an open label study to evaluate two different doses of KB301 in up to 20 subjects. Improvement of lateral canthal lines at rest was selected as a target indication for KB301 based upon the Phase 1 safety, efficacy and durability studies, which evaluated KB301 in the lower and upper cheek, including the lateral canthal region. Subjects will be followed for three months after KB301 treatment, and the study is expected to be completed in 2H 2023.<\/p>\n

\u201cWe have systematically assessed the safety, efficacy and durability of KB301 in multiple skin areas and have narrowed down to a target indication where there are no FDA-approved injectable treatments,\u201d said September Riharb, SVP of Jeune. \u201cWe plan to initiate a Phase 2 multicenter, double-blind randomized study of KB301 for the improvement of lateral canthal lines at rest following completion of the Phase 1 Cohort 3 study.\u201d<\/p>\n

Currently, there are no FDA-approved injectable aesthetic drugs indicated for lateral canthal lines at rest. In addition, there are no aesthetic treatment options that address the core cause of aged skin in the lateral canthal region where the thin, delicate skin next to the eye is prone to fine lines and wrinkles. Compounding this issue is the fact that lateral canthal lines at rest are one of the most requested aesthetic treatments by adult subjects of all ages.<\/p>\n

\n About the Phase 1 Study<\/strong>\n <\/p>\n

Previously, the Phase 1, or PEARL-1, study evaluated the safety, tolerability, initial efficacy and duration of effect of intradermal dose-ranging injections of KB301 in adult subjects. Data from the safety cohort of the PEARL-1 study showed<\/u><\/a> the safety and tolerability of repeat KB301 injections. On March 22, 2022, Jeune announced<\/u><\/a> positive proof-of-concept, safety and efficacy data with respect to improvement of fine lines and wrinkles from the efficacy cohort of the PEARL-1 study. On November 17, 2022, Jeune announced<\/u><\/a> data from the PEARL-1 extension cohort showing up to nine-month durability of effect following administration of high dose KB301. Details of the Phase 1 study can be found at www.clinicaltrials.gov<\/u><\/a> under NCT identifier NCT04540900.<\/p>\n

\n About Jeune Aesthetics, Inc.<\/strong>\n <\/p>\n

Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal Biotech, Inc., is a biotechnology company leveraging a clinically validated gene-delivery platform to fundamentally address \u2013 and reverse \u2013 the biology of aging skin. For more information, please visit http:\/\/www.jeuneinc.com<\/u><\/a>.<\/p>\n

\n About Krystal Biotech, Inc.<\/strong>\n <\/p>\n

Krystal Biotech, Inc.\u00a0(NASDAQ: KRYS) is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The Company\u2019s wide-ranging pipeline is based on its proprietary redosable HSV vector. Headquartered in\u00a0Pittsburgh, Pennsylvania, the Company is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization. For more information, please visit\u00a0http:\/\/www.krystalbio.com<\/u><\/a>, and follow @KrystalBiotech on\u00a0LinkedIn<\/u><\/a>\u00a0and\u00a0Twitter<\/u><\/a>.<\/p>\n

\n Forward-Looking Statements <\/strong>\n <\/p>\n

Any statements in this press release about future expectations, plans and prospects for Krystal Biotech, Inc., or its wholly-owned subsidiary, Jeune Aesthetics, Inc., including but not limited to statements about Jeune\u2019s pipeline of key skin proteins that it plans to advance through clinical development to create a new category of regenerative aesthetic medicine designed to address \u2013 and potentially reverse \u2013 biological changes in aging skin; the expectation that the Phase 1, Cohort 3 study will be to be completed in 2H 2023; Jeune\u2019s plans to initiate a Phase 2 multicenter, double-blind randomized study of KB301 for the improvement of lateral canthal lines at rest; and other statements containing the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201cpotential,\u201d \u201clikely,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccontinue,\u201d and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials will be indicative of the results of ongoing or future trials, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercial potential of product candidates including KB301 and such other important factors as are set forth under the caption \u201cRisk Factors\u201d in Krystal\u2019s annual and quarterly reports on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Krystal\u2019s and Jeune\u2019s views as of the date of this release. Krystal and Jeune anticipate that subsequent events and developments will cause their views to change. However, while Krystal and Jeune may elect to update these forward-looking statements at some point in the future, they specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing Krystal\u2019s and Jeune\u2019s views as of any date subsequent to the date of this release.<\/p>\n

\n CONTACT:<\/strong>\n <\/p>\n

Investors and Media:
Meg Dodge
Krystal Biotech
mdodge@krystalbio.com<\/u><\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PITTSBURGH, April 18, 2023 (GLOBE NEWSWIRE) — Jeune Aesthetics, Inc. (\u201cJeune\u201d), a wholly-owned subsidiary of Krystal Biotech, Inc. (\u201cKrystal\u201d) (NASDAQ: KRYS), today announced treatment of the first subject in the Phase 1, Cohort 3 study of KB301 for the improvement of lateral canthal lines at rest. Jeune\u2019s lead product candidate, KB301, delivers the human COL3A1 gene to targeted skin cells that in turn produce natural type 3 collagen. Natural collagen 3 is the first in a pipeline of key skin proteins that Jeune plans to advance through clinical development to create a new category of regenerative aesthetic medicines designed to address \u2013 and potentially reverse \u2013 biological changes in aging skin. The Phase 1, Cohort 3 study is being conducted … <\/p>\n

Continue reading “Jeune Aesthetics Announces Dosing of First Subject in Phase 1, Cohort 3 Study of KB301 for the Improvement of Lateral Canthal Lines at Rest”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-748444","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nJeune Aesthetics Announces Dosing of First Subject in Phase 1, Cohort 3 Study of KB301 for the Improvement of Lateral Canthal Lines at Rest - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jeune Aesthetics Announces Dosing of First Subject in Phase 1, Cohort 3 Study of KB301 for the Improvement of Lateral Canthal Lines at Rest - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PITTSBURGH, April 18, 2023 (GLOBE NEWSWIRE) — Jeune Aesthetics, Inc. (\u201cJeune\u201d), a wholly-owned subsidiary of Krystal Biotech, Inc. (\u201cKrystal\u201d) (NASDAQ: KRYS), today announced treatment of the first subject in the Phase 1, Cohort 3 study of KB301 for the improvement of lateral canthal lines at rest. Jeune\u2019s lead product candidate, KB301, delivers the human COL3A1 gene to targeted skin cells that in turn produce natural type 3 collagen. Natural collagen 3 is the first in a pipeline of key skin proteins that Jeune plans to advance through clinical development to create a new category of regenerative aesthetic medicines designed to address \u2013 and potentially reverse \u2013 biological changes in aging skin. The Phase 1, Cohort 3 study is being conducted … Continue reading "Jeune Aesthetics Announces Dosing of First Subject in Phase 1, Cohort 3 Study of KB301 for the Improvement of Lateral Canthal Lines at Rest"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-18T11:05:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwOTg1NyM1NTI5MDA2IzIyMDg4NjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Jeune Aesthetics Announces Dosing of First Subject in Phase 1, Cohort 3 Study of KB301 for the Improvement of Lateral Canthal Lines at Rest\",\"datePublished\":\"2023-04-18T11:05:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\\\/\"},\"wordCount\":949,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwOTg1NyM1NTI5MDA2IzIyMDg4NjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\\\/\",\"name\":\"Jeune Aesthetics Announces Dosing of First Subject in Phase 1, Cohort 3 Study of KB301 for the Improvement of Lateral Canthal Lines at Rest - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwOTg1NyM1NTI5MDA2IzIyMDg4NjI=\",\"datePublished\":\"2023-04-18T11:05:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwOTg1NyM1NTI5MDA2IzIyMDg4NjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwOTg1NyM1NTI5MDA2IzIyMDg4NjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jeune Aesthetics Announces Dosing of First Subject in Phase 1, Cohort 3 Study of KB301 for the Improvement of Lateral Canthal Lines at Rest\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Jeune Aesthetics Announces Dosing of First Subject in Phase 1, Cohort 3 Study of KB301 for the Improvement of Lateral Canthal Lines at Rest - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\/","og_locale":"en_US","og_type":"article","og_title":"Jeune Aesthetics Announces Dosing of First Subject in Phase 1, Cohort 3 Study of KB301 for the Improvement of Lateral Canthal Lines at Rest - Market Newsdesk","og_description":"PITTSBURGH, April 18, 2023 (GLOBE NEWSWIRE) — Jeune Aesthetics, Inc. (\u201cJeune\u201d), a wholly-owned subsidiary of Krystal Biotech, Inc. (\u201cKrystal\u201d) (NASDAQ: KRYS), today announced treatment of the first subject in the Phase 1, Cohort 3 study of KB301 for the improvement of lateral canthal lines at rest. Jeune\u2019s lead product candidate, KB301, delivers the human COL3A1 gene to targeted skin cells that in turn produce natural type 3 collagen. Natural collagen 3 is the first in a pipeline of key skin proteins that Jeune plans to advance through clinical development to create a new category of regenerative aesthetic medicines designed to address \u2013 and potentially reverse \u2013 biological changes in aging skin. The Phase 1, Cohort 3 study is being conducted … Continue reading \"Jeune Aesthetics Announces Dosing of First Subject in Phase 1, Cohort 3 Study of KB301 for the Improvement of Lateral Canthal Lines at Rest\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-18T11:05:52+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwOTg1NyM1NTI5MDA2IzIyMDg4NjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Jeune Aesthetics Announces Dosing of First Subject in Phase 1, Cohort 3 Study of KB301 for the Improvement of Lateral Canthal Lines at Rest","datePublished":"2023-04-18T11:05:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\/"},"wordCount":949,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwOTg1NyM1NTI5MDA2IzIyMDg4NjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\/","name":"Jeune Aesthetics Announces Dosing of First Subject in Phase 1, Cohort 3 Study of KB301 for the Improvement of Lateral Canthal Lines at Rest - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwOTg1NyM1NTI5MDA2IzIyMDg4NjI=","datePublished":"2023-04-18T11:05:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwOTg1NyM1NTI5MDA2IzIyMDg4NjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwOTg1NyM1NTI5MDA2IzIyMDg4NjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jeune-aesthetics-announces-dosing-of-first-subject-in-phase-1-cohort-3-study-of-kb301-for-the-improvement-of-lateral-canthal-lines-at-rest\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Jeune Aesthetics Announces Dosing of First Subject in Phase 1, Cohort 3 Study of KB301 for the Improvement of Lateral Canthal Lines at Rest"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/748444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=748444"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/748444\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=748444"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=748444"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=748444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}